Zacks Research Has Negative Forecast for MMSI Q4 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Zacks Research lowered their Q4 2024 earnings per share estimates for shares of Merit Medical Systems in a research report issued on Wednesday, November 20th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical instruments supplier will post earnings per share of $0.81 for the quarter, down from their previous estimate of $0.83. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q3 2026 earnings at $1.07 EPS.

Several other equities analysts have also weighed in on the stock. StockNews.com lowered shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $109.00 price target on shares of Merit Medical Systems in a report on Thursday, October 31st. Piper Sandler reissued an “overweight” rating and issued a $110.00 price objective (up previously from $100.00) on shares of Merit Medical Systems in a research note on Monday, September 9th. Barrington Research reaffirmed an “outperform” rating and set a $114.00 target price on shares of Merit Medical Systems in a research report on Thursday, October 31st. Finally, Wells Fargo & Company boosted their price target on shares of Merit Medical Systems from $85.00 to $103.00 and gave the company an “equal weight” rating in a research note on Monday, September 16th. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Merit Medical Systems has an average rating of “Moderate Buy” and a consensus price target of $103.36.

Merit Medical Systems Stock Up 0.3 %

Merit Medical Systems stock opened at $105.33 on Monday. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $6.14 billion, a PE ratio of 51.63, a PEG ratio of 2.61 and a beta of 0.89. The firm’s fifty day moving average is $98.59 and its 200 day moving average is $90.91. Merit Medical Systems has a 12-month low of $65.46 and a 12-month high of $106.87.

Merit Medical Systems (NASDAQ:MMSI) last released its earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 EPS for the quarter, topping the consensus estimate of $0.80 by $0.06. Merit Medical Systems had a return on equity of 15.61% and a net margin of 9.05%. The business had revenue of $339.85 million during the quarter, compared to analysts’ expectations of $334.60 million. During the same quarter last year, the firm posted $0.75 earnings per share. The firm’s revenue was up 7.8% on a year-over-year basis.

Insiders Place Their Bets

In other Merit Medical Systems news, Director F. Ann Millner sold 12,500 shares of Merit Medical Systems stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.55, for a total transaction of $1,269,375.00. Following the transaction, the director now owns 32,391 shares of the company’s stock, valued at $3,289,306.05. This trade represents a 27.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Raul Jr. Parra sold 29,646 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total value of $2,905,900.92. Following the completion of the transaction, the chief financial officer now directly owns 16,361 shares of the company’s stock, valued at approximately $1,603,705.22. This represents a 64.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Merit Medical Systems

Large investors have recently made changes to their positions in the business. American Century Companies Inc. increased its holdings in Merit Medical Systems by 2.9% during the second quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier’s stock worth $362,000 after buying an additional 118 shares during the last quarter. Xponance Inc. grew its position in shares of Merit Medical Systems by 4.9% during the 2nd quarter. Xponance Inc. now owns 3,621 shares of the medical instruments supplier’s stock valued at $311,000 after acquiring an additional 170 shares during the period. Glenmede Trust Co. NA increased its stake in shares of Merit Medical Systems by 0.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 28,637 shares of the medical instruments supplier’s stock worth $2,830,000 after purchasing an additional 170 shares during the last quarter. Captrust Financial Advisors raised its holdings in shares of Merit Medical Systems by 2.6% in the 3rd quarter. Captrust Financial Advisors now owns 7,440 shares of the medical instruments supplier’s stock worth $735,000 after purchasing an additional 187 shares during the period. Finally, TD Private Client Wealth LLC lifted its stake in Merit Medical Systems by 13.9% in the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock valued at $171,000 after purchasing an additional 211 shares during the last quarter. 99.66% of the stock is owned by hedge funds and other institutional investors.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.